-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS) Increases By 502.6%
Short Interest in DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS) Increases By 502.6%
DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating) was the target of a large increase in short interest in August. As of August 31st, there was short interest totalling 22,900 shares, an increase of 502.6% from the August 15th total of 3,800 shares. Based on an average daily trading volume, of 21,200 shares, the short-interest ratio is presently 1.1 days. Approximately 0.1% of the shares of the stock are short sold.
Institutional Investors Weigh In On DA32 Life Science Tech Acquisition
Several institutional investors and hedge funds have recently added to or reduced their stakes in DALS. Saba Capital Management L.P. purchased a new stake in shares of DA32 Life Science Tech Acquisition during the 1st quarter worth approximately $10,883,000. Sculptor Capital LP boosted its stake in DA32 Life Science Tech Acquisition by 0.5% during the second quarter. Sculptor Capital LP now owns 767,528 shares of the company's stock worth $7,438,000 after acquiring an additional 3,900 shares in the last quarter. Citadel Advisors LLC lifted its stake in shares of DA32 Life Science Tech Acquisition by 21.0% in the second quarter. Citadel Advisors LLC now owns 720,941 shares of the company's stock worth $6,986,000 after buying an additional 125,000 shares in the last quarter. RP Investment Advisors LP lifted its position in DA32 Life Science Tech Acquisition by 653.1% during the first quarter. RP Investment Advisors LP now owns 408,856 shares of the company's stock valued at $3,972,000 after purchasing an additional 354,569 shares during the period. Finally, Arena Capital Advisors LLC CA increased its stake in shares of DA32 Life Science Tech Acquisition by 327.5% in the first quarter. Arena Capital Advisors LLC CA now owns 326,328 shares of the company's stock worth $3,170,000 after purchasing an additional 250,000 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors.
Get DA32 Life Science Tech Acquisition alerts:DA32 Life Science Tech Acquisition Price Performance
Shares of NASDAQ:DALS remained flat at $9.74 during midday trading on Tuesday. The stock had a trading volume of 67 shares, compared to its average volume of 23,213. The business has a 50 day moving average of $9.72 and a two-hundred day moving average of $9.71. DA32 Life Science Tech Acquisition has a 1-year low of $9.58 and a 1-year high of $10.26.
DA32 Life Science Tech Acquisition Company Profile
(Get Rating)DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.
Read More
- Get a free copy of the StockNews.com research report on DA32 Life Science Tech Acquisition (DALS)
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
Receive News & Ratings for DA32 Life Science Tech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DA32 Life Science Tech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating) was the target of a large increase in short interest in August. As of August 31st, there was short interest totalling 22,900 shares, an increase of 502.6% from the August 15th total of 3,800 shares. Based on an average daily trading volume, of 21,200 shares, the short-interest ratio is presently 1.1 days. Approximately 0.1% of the shares of the stock are short sold.
DA32生命科學技術收購公司(納斯達克:DALS-GET Rating)是空頭股數8月份大幅增持的目標。截至8月31日,空頭股數共有22,900股,比8月15日的3,800股增加了502.6%。以日均成交量二萬一千二百股計算,目前短息比率為一點一天。大約0.1%的股票被賣空。
Institutional Investors Weigh In On DA32 Life Science Tech Acquisition
機構投資者參與收購DA32生命科學技術公司
Several institutional investors and hedge funds have recently added to or reduced their stakes in DALS. Saba Capital Management L.P. purchased a new stake in shares of DA32 Life Science Tech Acquisition during the 1st quarter worth approximately $10,883,000. Sculptor Capital LP boosted its stake in DA32 Life Science Tech Acquisition by 0.5% during the second quarter. Sculptor Capital LP now owns 767,528 shares of the company's stock worth $7,438,000 after acquiring an additional 3,900 shares in the last quarter. Citadel Advisors LLC lifted its stake in shares of DA32 Life Science Tech Acquisition by 21.0% in the second quarter. Citadel Advisors LLC now owns 720,941 shares of the company's stock worth $6,986,000 after buying an additional 125,000 shares in the last quarter. RP Investment Advisors LP lifted its position in DA32 Life Science Tech Acquisition by 653.1% during the first quarter. RP Investment Advisors LP now owns 408,856 shares of the company's stock valued at $3,972,000 after purchasing an additional 354,569 shares during the period. Finally, Arena Capital Advisors LLC CA increased its stake in shares of DA32 Life Science Tech Acquisition by 327.5% in the first quarter. Arena Capital Advisors LLC CA now owns 326,328 shares of the company's stock worth $3,170,000 after purchasing an additional 250,000 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors.
幾家機構投資者和對衝基金最近增持或減持了DALS的股份。薩巴資本管理公司在第一季度購買了DA32生命科學技術公司收購的新股份,價值約10,883,000美元。雕塑家Capital LP在第二季度將其在DA32生命科學技術公司收購中的股份增加了0.5%。雕塑家Capital LP現在擁有該公司767,528股股票,價值7,438,000美元,上個季度又收購了3,900股。Citadel Advisors LLC在第二季度將其在DA32 Life Science Tech收購的股份增加了21.0%。Citadel Advisors LLC現在持有該公司720,941股股票,價值6,98.6,000美元,上個季度又購買了125,000股。RP Investment Advisors LP在第一季度將其在DA32生命科學技術公司收購中的頭寸提高了653.1%。RP Investment Advisors LP現在擁有408,856股該公司的股票,價值3972,000美元,在此期間又購買了354,569股。最後,Arena Capital Advisors LLC CA在第一季度增持了DA32生命科學技術收購的股份327.5%。Arena Capital Advisors LLC CA現在擁有該公司326,328股股票,價值3,170,000美元,上個季度又購買了250,000股。60.43%的股票目前由機構投資者持有。
DA32 Life Science Tech Acquisition Price Performance
DA32生命科學技術收購價格表現
Shares of NASDAQ:DALS remained flat at $9.74 during midday trading on Tuesday. The stock had a trading volume of 67 shares, compared to its average volume of 23,213. The business has a 50 day moving average of $9.72 and a two-hundred day moving average of $9.71. DA32 Life Science Tech Acquisition has a 1-year low of $9.58 and a 1-year high of $10.26.
週二午盤交易中,納斯達克的股價持平於9.74美元。該股成交量為67股,而其平均成交量為23,213股。該業務的50日移動均線切入位在9.72美元,200日移動均線切入位在9.71美元。DA32生命科學技術收購的一年低點為9.58美元,一年高位為10.26美元。
DA32 Life Science Tech Acquisition Company Profile
DA32生命科學技術收購公司簡介
DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.
DA32生命科學技術收購公司沒有重大業務。它側重於與一個或多個企業進行合併、資本換股、資產收購、股票購買、重組或相關業務合併。該公司打算確定生物技術和生命科學基礎設施領域的業務合併目標。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on DA32 Life Science Tech Acquisition (DALS)
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- 免費獲取StockNews.com關於DA32生命科學技術收購(DALS)的研究報告
- 這就是現在對標準普爾500指數的預期
- 關於甲骨文的FQ1報告,你需要知道的兩件事
- 波動市場的三隻價值股
- 3個能源類股接近突破杯形格局
- 這些股息獲得者值得在你的投資組合中佔有一席之地嗎?
Receive News & Ratings for DA32 Life Science Tech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DA32 Life Science Tech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
獲得DA32生命科學技術收購日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對DA32生命科學技術收購和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧